Roles of 2 SARS-CoV-2 antibody assays in the diagnosis of corona virus disease 2019

doi:10.3969/j.issn.1673-8640.2020.12.022

Abstract

Abstract:

Objective To determine the immunoglobulin G（IgG） and IgM antibodies to severe acute respiratory syndrome coronavirus 2（SARS-CoV-2） by chemiluminescence and enzyme-linked immunosorbent assay（ELISA）. Methods A total of 116 patients diagnosed as COVID-19 and 346 patients without COVID-19 were enrolled,and serum SARS-CoV-2 IgG and IgM antibodies were determined by chemiluminescence and ELISA,respectively. Results The sensitivities,specificities and accuracies of chemiluminescence and ELISA determining serum SARS-CoV-2 IgG were 90.52% and 63.79%,98.84% and 96.53%,96.75% and 88.31%,respectively. The sensitivities,specificities and accuracies of determining serum SARS-CoV-2 IgM were 75.86% and 58.62%,99.42% and 97.4%,96.86% and 87.66%,respectively. Conclusions The determinations of serum SARS-CoV-2 IgG and IgM antibodies by chemiluminescence and ELISA have high sensitivities,specificities and accuracies. Clinical laboratories may choose suitable method according to actual situation.

Key words: Severe acute respiratory syndrome 2, Antibody, Chemiluminescence, Enzyme-linked immunosorbent assay, Corona virus disease 2019

CLC Number:

R446.1

HU Yan, SHEN Ge, LI Qiong, ZENG Ziyan, , YANG Gang, LI Ping, CHEN Yufeng, ZHANG Zhen, XIE Xiaobing. Roles of 2 SARS-CoV-2 antibody assays in the diagnosis of corona virus disease 2019[J]. Laboratory Medicine, 2020, 35(12): 1294-1297.

References 8

[1]	World Health Organization.Clinical management of severe acute respiratory infection when novel coronavirus(2019-nCoV) infection is suspected:interim guidance. 28 January 11,2020[S]. 2020.
[2]	HUI D S,I AZHAR E I,MADANI T A,et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health-the latest 2019 novel coronavirus outbreak in Wuhan,China[J]. Int J Infect Dis 2020,91:264-266.
[3]	国家卫生健康委办公厅. 新型冠状病毒肺炎诊疗方案(试行第七版)[EB/OL]. (2020-03-03)[2020-03-10]. .
[4]	里进,叶光明,陈良君,等. 新型冠状病毒核酸检测假阴性结果原因分析及对策[J]. 中华检验医学杂志,2020,43(3):221-225.
[5]	莫茜,秦炜,傅启华,等. 正确认识新冠病毒核酸检测的影响因素[J]. 中华检验医学杂志,2020,43(3):213-216.
[6]	郑培明,崔发财,张福明,等. 新型冠状病毒IgM/IgG抗体不同检测方法在新型冠状病毒感染中的临床应用评价[J]. 检验医学,2020,35(4):291-294.
[7]	徐万洲,李娟,何晓云,等. 血清2019新型冠状病毒IgM和IgG抗体联合检测在新型冠状病毒感染中的诊断价值[J]. 中华检验医学杂志,2020,43(3):230-233.
[8]	熊玲红,黄亚兰,孟君,等. 化学发光和酶联免疫吸附法检测SARS-CoV-2 IgM/IgG抗体比较[J/OL]. 热带医学杂志:1-6(2020-04-29)[2020-05-10]. .

[1]	SUN Xinlin, YE Xingming, LI Qian, ZHAO Lijun. Bronchoscopy combined with sputum Mycobacterium tuberculosis ribonucleic acid and serum Mycobacterium tuberculosis specific antibody determinations for diagnosis of negative pulmonary tuberculosis [J]. Laboratory Medicine, 2023, 38(9): 870-873.
[2]	DUAN Lili, JIANG Chang, ZHOU Dongmei. Role of PLR in ankylosing spondylitis patients with positive antinuclear antibody [J]. Laboratory Medicine, 2023, 38(7): 669-674.
[3]	XIAO Xiumei, LIANG Chao, LIU Caihong, LI Xiaoguang. Comparison of SARS-CoV-2 neutralizing antibody and specific antibody determination results [J]. Laboratory Medicine, 2023, 38(4): 352-356.
[4]	GAI Linlin, LI Haibo, CHU Jinjin, SUN Jiamei, YAN Xinyi, DU Jinke, DAI Wenqing, XU Donghua. Role of chemiluminescence interferon gamma release assay in auxiliary diagnosis of pulmonary tuberculosis [J]. Laboratory Medicine, 2023, 38(3): 257-260.
[5]	HE Xin, LI Yanping. Influence of disease types and clinical indexes on the CMIA determination results of anti-HCV antibody [J]. Laboratory Medicine, 2023, 38(3): 287-290.
[6]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[7]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[8]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[9]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[10]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[11]	DUAN Feiyun, HU Ruyuan, ZHAO Lina. Monitoring and analysis on measles antibody levels in females aged 20-40 in Dali Bai Autonomous Prefecture from 2016 to 2020 [J]. Laboratory Medicine, 2023, 38(10): 946-950.
[12]	YUE Caidie, LI Junyan, DING Aijun, XIE Li, ZENG Weikun. Research progress of rapid determination methods for SARS-CoV-2 antigen [J]. Laboratory Medicine, 2023, 38(1): 87-93.
[13]	LI Cheng, ZHOU Min, LEI Boya, CHANG Qing, CAO Wenjun, WANG Zhujian. Role of VZV DNA and IgG antibody determinations in aqueous humor of ARN patients in evaluation of antiviral efficacy [J]. Laboratory Medicine, 2022, 37(9): 831-834.
[14]	TAN Meiyu, SHU Jie, XUAN Binbin, ZHOU Lida, LI Hong, HOU Shangwei, SHENG Huiming. Effects of SARS-CoV-2 vaccination on antibody production and immune function [J]. Laboratory Medicine, 2022, 37(8): 729-734.
[15]	SUN Qi, QU Xinyi, XU Li. Analysis on outcome of patients with indeterminate western-blot results of HIV-1 antibody [J]. Laboratory Medicine, 2022, 37(8): 741-744.